Sagent gets approval for generic bladder inflammation treatment

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injectable drug for preventing bladder inflammation that can result from a certain chemotherapy treatment.

Sagent Pharmacueticals announced that the FDA had approved mesna in the 1 mg-per-milliliter strength, used to reduce the incidence of hemorrhagic cystitis caused by ifosfamide chemotherapy, itself used to treat testicular, bone and other cancers.

Mesna had sales of around $12 million in 2009, according to IMS Health.